test3

Attention Virginia Cancer Specialists Patients: There is a system outage and certain functions, such as scheduling, may not be available today. We will call patients to schedule any upcoming appointments when the system is back online. Our clinics remain open and previously scheduled appointments will continue as planned. We apologize for any inconvenience.

 

2020 World Conference on Lung Cancer - January 28 - 31, 2021 Alex Spira, MD, PhD, FACP

Virginia Cancer Specialists Practice Blog

January 28, 2021
Virginia Cancer Specialists » VCS Practice News » Events » VCS Practice News » 2020 World Conference on Lung Cancer » 2020 World Conference on Lung Cancer – January 28 – 31, 2021 Alex Spira, MD, PhD, FACP

Alex Spira, MD, PhD, FACP Presenting Author and Contributing author for multiple presentations for the 2020 World Conference on Lung Cancer – January 28 – 31, 2021

https://library.iaslc.org/search-speaker?search_speaker=87361

FP02 – Health Services Research/Health Economics

  • Event: WCLC 2020
  • Type: Posters (Featured)
  • Track: Health Services Research/Health Economics
  • Presentations: 1

FP02.02 – Real-World Outcomes Among Advanced Non-Small Cell Lung Cancer Patients Re-Treated with Immunotherapy in the US

00:00 – 00:00  |  Presenting Author(s): Alex I. Spira


OA03 – Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC

  • Event: WCLC 2020
  • Type: Oral
  • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
  • Presentations: 1

OA03.03 – Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study (ID 3407)

10:30 – 11:30  |  Presenting Author(s): Alex I. Spira

1/29/2021, 10:30 – 11:30, Scientific Program Auditorium


OA04 – New Data from Rare EGFR Alterations

  • Event: WCLC 2020
  • Type: Oral
  • Track: Targeted Therapy – Clinically Focused
  • Presentations: 1

OA04.04 – Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer (ID 3031)

11:45 – 12:45  |  Author(s): Alex I. Spira

1/29/2021, 11:45 – 12:45, Scientific Program Auditorium


P01 – Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics

  • Event: WCLC 2020
  • Type: Posters
  • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
  • Presentations: 1

P01.06 – CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase

00:00 – 00:00  |  Author(s): Alex I. Spira

1/28/2021, 00:00 – 00:00, ePoster Hall


P77 – Immunotherapy (Phase II/III Trials) – Combining Different Immunotherapeutic Approaches

  • Event: WCLC 2020
  • Type: Posters
  • Track: Immunotherapy (Phase II/III Trials)
  • Presentations: 1

77.02 – Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

00:00 – 00:00  |  Author(s): Alex I. Spira

1/28/2021, 00:00 – 00:00, ePoster Hall


P90 – Targeted Therapy – Clinically Focused – Misc. Topics

  • Event: WCLC 2020
  • Type: Posters
  • Track: Targeted Therapy – Clinically Focused
  • Presentations: 1

P90.03 – A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (ID 2968)

00:00 – 00:00  |  Presenting Author(s): Alex I. Spira


PS01 – Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

  • Event: WCLC 2020
  • Type: Plenary
  • Track: N.A.

Presentations: 1

PS01.07 – CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer (ID 3037)

07:00 – 09:00  |  Author(s): Alex I. Spira


PS02 – Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available) (ID 275)

  • Event: WCLC 2020
  • Type: Plenary
  • Track: N.A.
  • Presentations: 1

PS02.07 – CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer (ID 4290)

18:00 – 20:00  |  Author(s): Alex I. Spira